Tag: biologic & biosimilar ra drugs market overview

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Biologic & Biosimilar RA Drugs Industry By The Forecast Year 2029?

The market size for biologic & biosimilar ra drugs has experienced consistent expansion in recent years. It is forecast to rise from $13.99 billion in 2024 to $14.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to elements such as market adoption rates, clinical trial outcomes, changes in market share, long-term patient outcomes, and various pricing strategies.

The market for biologic & biosimilar ra drugs is projected to experience substantial expansion in the coming years. This market is anticipated to reach $19.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is attributable to factors such as accelerated biologic drug development, intense market competition, evolving healthcare policies, changing patient preferences, and ongoing clinical research & development. Key trends identified for this period encompass a surge in biosimilar market rivalry, the adoption of personalized medicine and precision therapy, innovations in drug delivery systems, an emphasis on safety and efficacy, and a shift towards patient-centric healthcare.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Drivers Are Supporting Growth Of The Biologic & Biosimilar RA Drugs Market?

The biologics and biosimilar RA drugs market is experiencing growth driven by the expanding elderly demographic and a greater occurrence of rheumatoid arthritis. Individuals aged 60 years or more are defined as the older population. Rheumatoid arthritis, an autoimmune condition, involves a person’s immune system attacking healthy cells, primarily impacting their joints. This condition predominantly affects seniors, as the immune system naturally weakens with advancing age. Compared to traditional medications, biologics and biosimilar RA drugs offer significant benefits in treating rheumatoid arthritis. For example, the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, reported approximately 1 billion individuals aged 60 and older globally in 2020, with projections indicating this demographic will expand to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, data from the Centers for Disease Control and Prevention, a US-based governmental public health agency, suggests that the count of adults with arthritis in the USA is anticipated to climb to 78.4 million by 2040, with 34.6 million potentially experiencing limitations in activities due to arthritis. Consequently, the growing senior population, coupled with a rise in rheumatoid arthritis instances, is propelling the biologics and biosimilar RA drugs market ahead.

Which Key Segments Fueling The Biologic & Biosimilar RA Drugs Market?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Are The Latest Industry Trends Transforming The Biologic & Biosimilar RA Drugs Market?

A significant trend gaining traction in the biologic & biosimilar RA drugs market involves novel innovations. Leading companies within the biologic & biosimilar RA drugs market are concentrating on creating biosimilar treatments, like Dual Concentration Biosimilar Options, to offer more economical choices. For example, in July 2023, Organon, a US-based healthcare firm, along with Samsung Bioepis, a South Korea-based biopharmaceutical enterprise, introduced HADLIMA, an adalimumab biosimilar of Humira, into the US market. Offered in both high and low concentrations, HADLIMA seeks to improve accessibility and lower costs for individuals suffering from autoimmune conditions. This biosimilar is retailed at an 85% discount compared to Humira, thus broadening patient availability. HADLIMA features an autoinjector, endorsed by the Arthritis Foundation, alongside a patient support initiative named HADLIMA For You, which provides educational materials and co-pay assistance. Its indications cover multiple conditions, such as rheumatoid arthritis and Crohn’s disease. HADLIMA comes in both a citrate-free high concentration (100 mg/mL) and a citrate-containing low concentration (50 mg/mL), ensuring uninterrupted care for patients.

Which Leading Companies Dominate The Biologic & Biosimilar RA Drugs Market Share?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biologic & Biosimilar RA Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Biologic & Biosimilar RA Drugs Market Valuation Change Between Now And 2029?

The market size for biologic & biosimilar ra drugs has been experiencing steady growth in recent past. The figures are set to rise further from $13.99 billion in 2024 to $14.57 billion in 2025, marking a compound annual growth rate (CAGR) of 4.1%. The growth seen in the previous periods can be traced back to factors such as the rate of market adoption, results of clinical trials, changing market shares, long-term results in patients, and pricing tactics.

Expectations are high for a robust expansion in the biologic & biosimilar ra drugs market in the coming years, with projections indicating that it will reach “$19.08 billion by 2029 at a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this forecasted growth include an increase in the development of biologic drugs, competition within the market, evolving healthcare policies, patient choices, and advancements in clinical research & development. Key trends to note in this forecast period are the rise in competition in the biosimilar market, development of personalized medicine and precision therapy, enhancement of drug delivery systems and a focus on safety, efficacy and patient-centered healthcare.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

What Are The Primary Factors Supporting The Biologic & Biosimilar RA Drugs Market Expansion?

The upward trend in the elderly demographic and the escalation in occurrences of rheumatoid arthritis are propelling the market for biologics and biosimilar RA drugs. The elderly demographic is comprised of individuals who are 60 years of age or older. Rheumatoid arthritis is an autoimmune disorder where the immune system turns on the body’s own cells, predominantly affecting the joints. This disease is more prevalent in older ages due to the immune system’s vulnerability as it weakens. Biologics and biosimilar RA drugs have proven to be a practical solution for treating rheumatoid arthritis in comparison to traditional drugs. For example, the World Health Organization (WHO), a health-focused subsidiary of the United Nations based in Switzerland, reported that approximately 1 billion individuals aged 60 and above were in the world in 2020, and this demographic is projected to escalate to 1.4 billion by 2030, and further to 2.1 billion by 2050. In addition, the Centers for Disease Control and Prevention, a public health organization operated by the US government, predicts that the number of US adults living with arthritis will rise to 78.4 million by 2040, and 34.6 million may experience limitations in activities as a result of arthritis. Consequently, the expansion of the aged population coupled with the growing incidents of RA is boosting the market for biologics and biosimilar RA drugs.

Which Segmentation Factors Are Critical In The Biologic & Biosimilar RA Drugs Market Analysis?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Are The Dominant Trends Currently Seen In The Biologic & Biosimilar RA Drugs Market?

One of the key trends in the biologic & biosimilar RA drugs market is the innovation of new treatments. Major companies are focusing on creating biosimilar treatments like Dual Concentration Biosimilar Options as affordable alternatives. In July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a biopharmaceutical company from South Korea, introduced their biosimilar of Humira (adalimumab), HADLIMA, in the US. With both high and low concentrations available, their aim is to increase accessibility and affordability for autoimmune disease patients. HADLIMA has an 85% price drop compared to Humira, thus, allowing more patients to access the treatment. The Arthritis Foundation recognizes the HADLIMA autoinjector and the patient support program, HADLIMA For You provides educational resources and co-pay support. The biosimilar is indicated for various conditions, including rheumatoid arthritis and Crohn’s disease. Available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), HADLIMA ensures uninterrupted care continuity for patients.

Who Are The Dominant Players In The Biologic & Biosimilar RA Drugs Market Today?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?

The market size for biologic and biosimilar RA drugs has seen a consistent increase recently. It is estimated to rise from $13.99 billion in 2024 to $14.57 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors contributing to growth in the historic period include market adoption rates, results of clinical trials, changes in market share, outcomes of long-term patient treatment, and pricing strategies.

The market size for biologic & biosimilar RA drugs is predicted to experience robust expansion in the coming years, increasing to “$19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%.” Factors contributing to this projected growth in the forecast period include the escalation in biologic drug creation, competitive dynamics, healthcare policies, patient predilections, and clinical research & advances. The forecast period is also expected to see emerging trends such as increased competition in the biosimilar market, personalized medicine and precision therapy, advancements in drug delivery solutions, emphasis on safety and effectiveness, and patient-focused healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?

The biologics and biosimilar RA drugs market is being propelled by the growth in the aging population and the escalating prevalence of rheumatoid arthritis. The term aging population pertains to individuals who are 60 years old or above. An autoimmune disorder, rheumatoid arthritis, occurs when a person’s immune system assails its own healthy cells, impacting the individual’s joints. The likelihood of rheumatoid arthritis heightens in older people, as the immune system weakens as one gets older. Compared to traditional drugs, biologics and biosimilar RA drugs serve as effective treatment options for rheumatoid arthritis. As reported by the World Health Organization (WHO), a specialized health entity of the United Nations situated in Switzerland, approximately 1 billion individuals aged 60 and above were present globally in 2020, a figure anticipated to surge to 1.4 billion by 2030, and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a governmental public health agency based in the US, predicts that by 2040, around 78.4 million adults in the USA will be afflicted with arthritis, while about 34.6 million people might experience limitations in activities due to arthritis. Therefore, the expansion in the number of elderly individuals combined with the rise in RA instances is enhancing the progress of the biologics and biosimilars RA drugs market.

Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Future Market Trends Are Projected For The Biologic & Biosimilar RA Drugs Industry?

The advancement of new innovations holds significance as a majority trend in the biologic & biosimilar RA drugs market. The focus of major corporations in this market is on creating biosimilar therapies such as Dual Concentration Biosimilar Options as cost-effective substitutes. To illustrate, in July 2023, Organon, a healthcare firm based in the US, along with Samsung Bioepis from South Korea, introduced a biosimilar treatment, HADLIMA, a version of Humira (adalimumab), in the United States. The dual concentration biosimilar, delivering both high and low concentrations, endeavors to increase accessibility and affordability for autoimmune patients. Being priced 85% lower than Humira enhances patient reach. Further affirmed by the Arthritis Foundation, HADLIMA brings with it an autoinjector and a patient assistance program named HADLIMA For You, providing educational support and co-pay assistance. It is prescribed for diverse conditions, including rheumatoid arthritis and Crohn’s disease. Patients can access HADLIMA in citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL), ensuring uninterrupted patient care.

Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?

The market size for biologic and biosimilar RA drugs has seen a consistent increase recently. It is estimated to rise from $13.99 billion in 2024 to $14.57 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors contributing to growth in the historic period include market adoption rates, results of clinical trials, changes in market share, outcomes of long-term patient treatment, and pricing strategies.

The market size for biologic & biosimilar RA drugs is predicted to experience robust expansion in the coming years, increasing to “$19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%.” Factors contributing to this projected growth in the forecast period include the escalation in biologic drug creation, competitive dynamics, healthcare policies, patient predilections, and clinical research & advances. The forecast period is also expected to see emerging trends such as increased competition in the biosimilar market, personalized medicine and precision therapy, advancements in drug delivery solutions, emphasis on safety and effectiveness, and patient-focused healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?

The biologics and biosimilar RA drugs market is being propelled by the growth in the aging population and the escalating prevalence of rheumatoid arthritis. The term aging population pertains to individuals who are 60 years old or above. An autoimmune disorder, rheumatoid arthritis, occurs when a person’s immune system assails its own healthy cells, impacting the individual’s joints. The likelihood of rheumatoid arthritis heightens in older people, as the immune system weakens as one gets older. Compared to traditional drugs, biologics and biosimilar RA drugs serve as effective treatment options for rheumatoid arthritis. As reported by the World Health Organization (WHO), a specialized health entity of the United Nations situated in Switzerland, approximately 1 billion individuals aged 60 and above were present globally in 2020, a figure anticipated to surge to 1.4 billion by 2030, and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a governmental public health agency based in the US, predicts that by 2040, around 78.4 million adults in the USA will be afflicted with arthritis, while about 34.6 million people might experience limitations in activities due to arthritis. Therefore, the expansion in the number of elderly individuals combined with the rise in RA instances is enhancing the progress of the biologics and biosimilars RA drugs market.

Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Future Market Trends Are Projected For The Biologic & Biosimilar RA Drugs Industry?

The advancement of new innovations holds significance as a majority trend in the biologic & biosimilar RA drugs market. The focus of major corporations in this market is on creating biosimilar therapies such as Dual Concentration Biosimilar Options as cost-effective substitutes. To illustrate, in July 2023, Organon, a healthcare firm based in the US, along with Samsung Bioepis from South Korea, introduced a biosimilar treatment, HADLIMA, a version of Humira (adalimumab), in the United States. The dual concentration biosimilar, delivering both high and low concentrations, endeavors to increase accessibility and affordability for autoimmune patients. Being priced 85% lower than Humira enhances patient reach. Further affirmed by the Arthritis Foundation, HADLIMA brings with it an autoinjector and a patient assistance program named HADLIMA For You, providing educational support and co-pay assistance. It is prescribed for diverse conditions, including rheumatoid arthritis and Crohn’s disease. Patients can access HADLIMA in citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL), ensuring uninterrupted patient care.

Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?

The market size for biologic and biosimilar RA drugs has seen a consistent increase recently. It is estimated to rise from $13.99 billion in 2024 to $14.57 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors contributing to growth in the historic period include market adoption rates, results of clinical trials, changes in market share, outcomes of long-term patient treatment, and pricing strategies.

The market size for biologic & biosimilar RA drugs is predicted to experience robust expansion in the coming years, increasing to “$19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%.” Factors contributing to this projected growth in the forecast period include the escalation in biologic drug creation, competitive dynamics, healthcare policies, patient predilections, and clinical research & advances. The forecast period is also expected to see emerging trends such as increased competition in the biosimilar market, personalized medicine and precision therapy, advancements in drug delivery solutions, emphasis on safety and effectiveness, and patient-focused healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?

The biologics and biosimilar RA drugs market is being propelled by the growth in the aging population and the escalating prevalence of rheumatoid arthritis. The term aging population pertains to individuals who are 60 years old or above. An autoimmune disorder, rheumatoid arthritis, occurs when a person’s immune system assails its own healthy cells, impacting the individual’s joints. The likelihood of rheumatoid arthritis heightens in older people, as the immune system weakens as one gets older. Compared to traditional drugs, biologics and biosimilar RA drugs serve as effective treatment options for rheumatoid arthritis. As reported by the World Health Organization (WHO), a specialized health entity of the United Nations situated in Switzerland, approximately 1 billion individuals aged 60 and above were present globally in 2020, a figure anticipated to surge to 1.4 billion by 2030, and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a governmental public health agency based in the US, predicts that by 2040, around 78.4 million adults in the USA will be afflicted with arthritis, while about 34.6 million people might experience limitations in activities due to arthritis. Therefore, the expansion in the number of elderly individuals combined with the rise in RA instances is enhancing the progress of the biologics and biosimilars RA drugs market.

Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Future Market Trends Are Projected For The Biologic & Biosimilar RA Drugs Industry?

The advancement of new innovations holds significance as a majority trend in the biologic & biosimilar RA drugs market. The focus of major corporations in this market is on creating biosimilar therapies such as Dual Concentration Biosimilar Options as cost-effective substitutes. To illustrate, in July 2023, Organon, a healthcare firm based in the US, along with Samsung Bioepis from South Korea, introduced a biosimilar treatment, HADLIMA, a version of Humira (adalimumab), in the United States. The dual concentration biosimilar, delivering both high and low concentrations, endeavors to increase accessibility and affordability for autoimmune patients. Being priced 85% lower than Humira enhances patient reach. Further affirmed by the Arthritis Foundation, HADLIMA brings with it an autoinjector and a patient assistance program named HADLIMA For You, providing educational support and co-pay assistance. It is prescribed for diverse conditions, including rheumatoid arthritis and Crohn’s disease. Patients can access HADLIMA in citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL), ensuring uninterrupted patient care.

Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?

In the past few years, the market size for biologic and biosimilar ra drugs has shown a consistent growth. The market is expected to expand from $13.99 billion in 2024 to $14.57 billion in 2025, representing a compound annual growth rate (CAGR) of 4.1%. Factors such as market adoption rates, results of clinical trials, changes in market share, long-term patient outcomes, and pricing strategies can be credited for the growth during the historic period.

The market for biologic & biosimilar ra drugs is forecasted to experience robust expansion in the upcoming years, reaching a worth of $19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This expected growth during the forecast period is due to factors such as enhanced biologic drug creation, industry rivalry, healthcare reforms, patient choices, and clinical research & innovation. Some of the major trends projected for this period are an increase in biosimilar market rivalry, custom-tailored medicine and precision treatment, advancements in medication delivery methods, prioritizing safety and effectiveness, and a more patient-focused approach to healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?

The escalating elderly population, coupled with a rising occurrence of rheumatoid arthritis, stimulates growth in the biologics and biosimilar RA drugs market. The term “older population” denotes individuals aged 60 or above. An autoimmune disorder, rheumatoid arthritis produces a response whereby a person’s immune system targets its healthy cells, impacting the person’s joints. This condition is particularly prevalent amongst the elderly as the immune system diminishes with age. Biologics and biosimilar RA drugs offer significantly effective treatment for rheumatoid arthritis when compared to traditional medications. For instance, The World Health Organization (WHO), a UN-affiliated specialized health entity based in Switzerland, reported approximately 1 billion seniors aged 60 and above globally in 2020. Moreover, this demographic is forecasted to surge to 1.4 billion by 2030 and ultimately reach 2.1 billion by 2050. Besides, the Centers for Disease Control and Prevention, a US government public health entity, predicted that the number of adults afflicted by arthritis in the USA could rise to 78.4 million by 2040. Meanwhile, arthritis-related activity limitations might impact 34.6 million people. Consequently, the augmenting elderly population, combined with an increase in RA cases, fuels the expansion of the biologics and biosimilars RA drugs market.

Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

How Are Key Trends Driving Expansion In The Biologic & Biosimilar RA Drugs Industry?

The rising popularity in the biologic & biosimilar RA drugs market is greatly influenced by new innovations. To provide a more affordable option, leading companies in this sector are focused on creating biosimilar treatments like Dual Concentration Biosimilar Options. Notably, Organon, an American healthcare company, teamed up with Samsung Bioepis, a biopharmaceutical company based in South Korea, to debut HADLIMA, a Humira (adalimumab) biosimilar, in the US in July 2023. HADLIMA, offered in both high and low concentrations, aims to improve accessibility and affordability for those struggling with autoimmune diseases. The biosimilar is available at a whopping 85% discount compared to Humira, thereby facilitating improved access for patients. The Arthritis Foundation has recognized HADLIMA’s autoinjector, and a patient support program named HADLIMA For You also accompanies the biosimilar, granting educational resources and co-pay assistance. This medication is recommended for multiple health conditions including Crohn’s disease and rheumatoid arthritis. Available in both citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL) forms, HADLIMA ensures an uninterrupted continuity of care for patients.

Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Biologic & Biosimilar RA Drugs Market?

The market size of biologic & biosimilar RA drugs has experienced significant growth in the past few years. It is projected to expand from $13.99 billion in 2024 to $14.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historical period include market adoption rates, results of clinical trials, changes in market share, long-term patient outcomes, and pricing strategies.

What Growth Rate Is Forecasted for the Biologic & Biosimilar RA Drugs Market by 2029?

The market size of biologic and biosimilar ra drugs is anticipated to experience considerable growth in the forthcoming years, expanding to $19.51 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 7.3%. The increase during the forecast period can be credited to the growth of biologic drug production, competitive markets, healthcare regulations, patient choices, and clinical research and development. Key trends projected during this period encompass an increase in competitive biosimilar markets, tailored treatments and precision therapy, improved drug delivery technologies, emphasis on safety and efficiency, and a patient-oriented healthcare approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Key Companies Are Shaping the Future of the Biologic & Biosimilar RA Drugs Market?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Which Factors Are Driving Demand in the Biologic & Biosimilar RA Drugs Industry?

The burgeoning geriatric population and a spike in rheumatoid arthritis cases are propelling the biologics and biosimilar RA drugs market. The geriatric population comprises individuals aged 60 years and above. Rheumatoid arthritis is an autoimmune disorder which causes the body’s immune system to assault its healthy cells, leading to joint affliction. The probability of developing this disease amplifies with aging as the immune system weakens. Biologics and biosimilar RA drugs are more effective in treating rheumatoid arthritis than traditional drugs. For example, the World Health Organization (WHO), a health sector of the United Nations in Switzerland, reported that there were approximately 1 billion people worldwide over 60 in the year 2020. This figure is anticipated to escalate to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a US government health agency, predict that the number of adults in the US with arthritis could potentially rise to 78.4 million by 2040, with 34.6 million individuals handling arthritis-related mobility restrictions. Consequently, the escalating elderly population combined with a rise in RA incidences is stimulating growth in the biologics and biosimilars RA drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

How Is the Biologic & Biosimilar RA Drugs Market Segmented by Several Divisions?

The biologic & biosimilar RA drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What are the Emerging Market Trends Driving the Growth of the Biologic & Biosimilar RA Drugs Industry?

The biologic & biosimilar RA drugs market is seeing a rise in popularity due to cutting-edge innovations. A primary focal point for significant companies in this field is the creation of biosimilar treatments, such as Dual Concentration Biosimilar Options, offering a cost-effective substitution. In July 2023, for example, Organon, an American healthcare firm, together with Samsung Bioepis, a biopharmaceutical company from South Korea, introduced a biosimilar of Humira (adalimumab) to the US market named HADLIMA. This product, which can be accessed in high and low concentrations, facilitates improved affordability and access for patients suffering from autoimmune diseases. The price of the biosimilar is 85% lower than Humira, leading to an increase in patient access. The Arthritis Foundation endorses HADLIMA’s included autoinjector, and the patient support program named HADLIMA For You, which supplies educational resources and co-pay assistance. HADLIMA can be used to treat a variety of conditions, such as rheumatoid arthritis and Crohn’s disease. It comes in citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) for a consistent patient care.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Regions Are Driving Growth in the Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255

This Report Delivers Insight On:

1. How big is the biologic & biosimilar ra drugs market, and how is it changing globally?

2. Who are the major companies in the biologic & biosimilar ra drugs market, and how are they performing?

3. What are the key opportunities and risks in the biologic & biosimilar ra drugs market right now?

4. Which products or customer segments are growing the most in the biologic & biosimilar ra drugs market?

5. What factors are helping or slowing down the growth of the biologic & biosimilar ra drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Biologic & Biosimilar RA Drugs Market?

The market size of biologic & biosimilar RA drugs has experienced significant growth in the past few years. It is projected to expand from $13.99 billion in 2024 to $14.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historical period include market adoption rates, results of clinical trials, changes in market share, long-term patient outcomes, and pricing strategies.

What Growth Rate Is Forecasted for the Biologic & Biosimilar RA Drugs Market by 2029?

The market size of biologic and biosimilar ra drugs is anticipated to experience considerable growth in the forthcoming years, expanding to $19.51 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 7.3%. The increase during the forecast period can be credited to the growth of biologic drug production, competitive markets, healthcare regulations, patient choices, and clinical research and development. Key trends projected during this period encompass an increase in competitive biosimilar markets, tailored treatments and precision therapy, improved drug delivery technologies, emphasis on safety and efficiency, and a patient-oriented healthcare approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Key Companies Are Shaping the Future of the Biologic & Biosimilar RA Drugs Market?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Which Factors Are Driving Demand in the Biologic & Biosimilar RA Drugs Industry?

The burgeoning geriatric population and a spike in rheumatoid arthritis cases are propelling the biologics and biosimilar RA drugs market. The geriatric population comprises individuals aged 60 years and above. Rheumatoid arthritis is an autoimmune disorder which causes the body’s immune system to assault its healthy cells, leading to joint affliction. The probability of developing this disease amplifies with aging as the immune system weakens. Biologics and biosimilar RA drugs are more effective in treating rheumatoid arthritis than traditional drugs. For example, the World Health Organization (WHO), a health sector of the United Nations in Switzerland, reported that there were approximately 1 billion people worldwide over 60 in the year 2020. This figure is anticipated to escalate to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a US government health agency, predict that the number of adults in the US with arthritis could potentially rise to 78.4 million by 2040, with 34.6 million individuals handling arthritis-related mobility restrictions. Consequently, the escalating elderly population combined with a rise in RA incidences is stimulating growth in the biologics and biosimilars RA drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

How Is the Biologic & Biosimilar RA Drugs Market Segmented by Several Divisions?

The biologic & biosimilar RA drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What are the Emerging Market Trends Driving the Growth of the Biologic & Biosimilar RA Drugs Industry?

The biologic & biosimilar RA drugs market is seeing a rise in popularity due to cutting-edge innovations. A primary focal point for significant companies in this field is the creation of biosimilar treatments, such as Dual Concentration Biosimilar Options, offering a cost-effective substitution. In July 2023, for example, Organon, an American healthcare firm, together with Samsung Bioepis, a biopharmaceutical company from South Korea, introduced a biosimilar of Humira (adalimumab) to the US market named HADLIMA. This product, which can be accessed in high and low concentrations, facilitates improved affordability and access for patients suffering from autoimmune diseases. The price of the biosimilar is 85% lower than Humira, leading to an increase in patient access. The Arthritis Foundation endorses HADLIMA’s included autoinjector, and the patient support program named HADLIMA For You, which supplies educational resources and co-pay assistance. HADLIMA can be used to treat a variety of conditions, such as rheumatoid arthritis and Crohn’s disease. It comes in citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) for a consistent patient care.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Regions Are Driving Growth in the Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255

This Report Delivers Insight On:

1. How big is the biologic & biosimilar ra drugs market, and how is it changing globally?

2. Who are the major companies in the biologic & biosimilar ra drugs market, and how are they performing?

3. What are the key opportunities and risks in the biologic & biosimilar ra drugs market right now?

4. Which products or customer segments are growing the most in the biologic & biosimilar ra drugs market?

5. What factors are helping or slowing down the growth of the biologic & biosimilar ra drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theBiologic & Biosimilar RA Drugs Market from 2025 to 2034?

The biologics and biosimilar RA drugs market is being propelled by an increasing elderly populace and a rising prevalence of rheumatoid arthritis. The term “elderly population” is applicable to those who are 60 years old or above. Rheumatoid arthritis is an autoimmune sickness where a person’s immune system mistakenly attacks its own healthy cells, predominantly affecting the joints. The likelihood of developing rheumatoid arthritis increases with age as the immune system weakens. Biologics and biosimilar RA medications demonstrate remarkable effectiveness for rheumatoid arthritis treatment compared to conventional drugs. As per the data shared by the World Health Organization (WHO), a Switzerland-based branch of the United Nations that focuses on health-related issues, nearly 1 billion people were aged 60 and above globally in 2020. This population is estimated to surge to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, the Centers for Disease Control and Prevention, a US government agency dedicated to public health, anticipates that the number of US adults suffering from arthritis will reach 78.4 million by 2040, with about 34.6 million people possibly experiencing limitations due to arthritis-related activities. Hence, this growth in the elderly population and rise in RA cases is propelling the biologics and biosimilars RA drugs market forward.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

How Has the Biologic & Biosimilar RA Drugs Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The market size for biologic & biosimilar ra drugs has seen considerable growth in the past few years. The market is projected to escalate from $13.99 billion in 2024 to around $14.71 billion in 2025, representing a compound annual growth rate (CAGR) of 5.2%. The surge during the historical period can be linked to factors like adoption rates in the market, results of clinical trials, changes in market share, long-term results for patients, and pricing strategies.

The market size for biologic and biosimilar ra drugs is predicted to experience robust growth in the coming years. It is expected to enlarge to $19.51 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 7.3%. The anticipated growth during the forecast period is due to factors such as advancements in biologic drug creation, increased market rivalry, changes in healthcare policies, shifting patient choices, and progress in scientific research and development. Key future trends are likely to encompass a heightened competition within the biosimilar market, advances in personalised medicine and precision therapy, improvements in drug delivery mechanisms, an emphasis on safety and effectiveness, and a greater focus on patient-oriented healthcare.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255

How Are Market Trends and Innovations Revolutionizing theBiologic & Biosimilar RA Drugs Industry in Recent Times?

A crucial trend for success in the biologic & biosimilar RA drugs market are recent innovations. A key focus for major corporations in this industry is developing biosimilar treatments such as Dual Concentration Biosimilar Options that could offer budget-friendly alternatives. Organon, an American healthcare organization, and Samsung Bioepis, a biopharmaceutical firm in South Korea, introduced a biosimilar of Humira (adalimumab), known as HADLIMA, in the US in July 2023. Offering both high and low concentration options, HADLIMA is designed to increase accessibility and cost-effectiveness for autoimmune patients. Remarkably, the biosimilar is set 85% cheaper than Humira, thus broadening patient reach. Among its features, HADLIMA comes with an autoinjector, approved by the Arthritis Foundation, and a patient assistance program, HADLIMA For You, providing educational content and co-pay assistance. It’s prescribed for numerous conditions, including rheumatoid arthritis and Crohn’s disease. Importantly, HADLIMA is offered in both a citrate-free high concentration (100 mg/mL), and a citrate-inclusive lower concentration (50 mg/mL), ensuring uninterrupted care for patients.

Which Key Market Players Are Shaping the Future and Growth of theBiologic & Biosimilar RA Drugs Market?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

What Are the Core Segments of the Biologic & Biosimilar RA Drugs Market, and How Do They Contribute to Growth?

The biologic & biosimilar RA drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smpGlobal Biologic & Biosimilar RA Drugs Market, Global Biologic & Biosimilar RA Drugs Market Report, Global Biologic & Biosimilar RA Drugs Market Trends, Global Biologic & Biosimilar RA Drugs Market Size

Browse Through More Reports Similar to the Gobal Biologic & Biosimilar RA Drugs Maret 2025, By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: